Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II Study of TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT01328574
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:36:19.575248+00:00
Published At
2015-03-02T00:00:00+00:00
Record Updated At
2017-01-13
Results Posted At
2015-03-02
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Urothelial Carcinoma", "Ureteral Neoplasms", "Ureter Cancer", "Neoplasm, Ureteral", "Cancer of the Ureter"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2017-01-13"
protocolSection.identificationModule.nctId
"NCT01328574"
protocolSection.identificationModule.officialTitle
"A Phase II Study of TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2015-03-02"

Study condition terms

  • Urothelial Carcinoma (protocolSection.conditionsModule.conditions)
  • Ureteral Neoplasms (protocolSection.conditionsModule.conditions)
  • Ureter Cancer (protocolSection.conditionsModule.conditions)
  • Neoplasm, Ureteral (protocolSection.conditionsModule.conditions)
  • Cancer of the Ureter (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.